---
title: >-
  Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term
  Complications In Ulcerative Colitis: Findings From TARGET-IBD.
description: >-
  Explore this publication on real-world evidence: Impact Of Early Endoscopic
  Remission After Advanced Therapy On Long-Term Complications In Ulcerative
  Colitis:…
date: '2026-01-01'
category: Publications
tags:
  - Poster Presentation
  - R&D
  - Care
  - Gastroenterology
  - GI - Other
  - Pharma Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/poster-presentation/impact-of-early-endoscopic-remission-after-advanced-therapy/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: impact-of-early-endoscopic-remission-after-advanced-therapy
id: 6v4t6RT3G1oo5hB8IvNuKf
contentType: article
---

## Challenge

Achieving early endoscopic remission is a key treat-to-target goal in UC, but real-world evidence linking early endoscopic remission after advanced therapy initiation to long-term reductions in complications—hospitalization, colectomy, disease progression—had not been established in a large prospective US cohort.

## Solution

The TARGET-IBD registry was used to compare long-term complication rates between UC patients who achieved early endoscopic remission after advanced therapy and those who did not, using time-to-event analyses to quantify the downstream benefits of achieving the treat-to-target endpoint.

## Impact

Demonstrating that early endoscopic remission after advanced therapy is associated with significantly lower rates of long-term UC complications provides the clinical meaningfulness evidence for endoscopic remission as a treat-to-target endpoint, directly supporting Merck's regulatory and payer strategy for its UC portfolio.